vTv Therapeutics Inc.: 10-Q filed 2016-11-03
What vTv Therapeutics Inc. reported in its quarterly report filed 2016-11-03 (fiscal Q3 2016): 24 published measures, 65 facts as tagged in accession 0001564590-16-027390.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-11-03
- Fiscal period
- fiscal Q3 2016
- Accession
- 0001564590-16-027390 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All vTv Therapeutics Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 54,715,000 | USD | |
| At 2015-12-31 | 91,532,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 10,808,000 | USD | |
| At 2015-12-31 | 7,971,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | -111,240,000 | USD | |
| At 2015-12-31 | -77,970,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 51,058,000 | USD | |
| At 2015-12-31 | 88,003,000 | USD | |
| At 2015-09-30 | 97,010,000 | USD | |
| At 2014-12-31 | 1,384,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -3,993,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -12,302,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -4,103,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -24,329,000 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 87,000 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 42,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | -234,407,000 | USD | |
| At 2015-12-31 | -195,985,000 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 0 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 0 | USD | 274 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 493,000 | USD | |
| At 2015-12-31 | 624,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 1,988,000 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 304,000 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -13,528,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -41,707,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -9,441,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -27,052,000 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 52,116,000 | USD | |
| At 2015-12-31 | 89,186,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 10,583,000 | USD | |
| At 2015-12-31 | 7,726,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 0 | USD | |
| At 2015-12-31 | 69,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 13,566,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 42,303,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 9,574,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 27,345,000 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 10,636,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 33,854,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 6,574,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 19,106,000 | USD | 273 |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 2,103,000 | USD | |
| At 2015-12-31 | 1,673,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 1,058,000 | USD | |
| At 2015-12-31 | 1,114,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -13,505,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -41,642,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -9,822,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -30,048,000 | USD | 273 |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -13,505,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -41,642,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -9,822,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -30,048,000 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 2,401,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 7,654,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 2,415,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 6,707,000 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 216,000 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 361,000 | USD | 273 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 2,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 2,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -1,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -851,000 | USD | 273 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | -69,000 | USD | 274 |
Inspect the source
- Entity
- vTv Therapeutics Inc. / CIK 0001641489
- Captured
- SEC response SHA-256
a4077830f75ab31b4bd255a2506ae68d2ee3fea6951db63b4abf956f42ed7e7d
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001641489.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))